MintNeuro lands $5M to commercialize neural-interface chips
MintNeuro, a neurotechnology chip startup spun out of Imperial College London, has raised $5 million to move its semiconductor platform toward commercial production. The company develops modular chips for neural sensing, signal processing, and stimulation used in brain-computer interfaces and implants. The funding will also support more pre-release silicon for partners and expansion in the United States.
MintNeuro is a London-based company that originated at Imperial College London. Its $5 million round was led by Odyssey Ventures, with 33East, JSK Investments and Alumni Ventures participating; Empirical Ventures, Jumpspace Ventures and earlier investors also returned. The startup intends to shift from validation to commercial production, supply more pre-release silicon to partners, and expand in the U.S.
Its modular chips are designed for neural sensing, signal processing and stimulation. MintNeuro reports functional chips and integration progress with Motif Neurotech and Amber Therapeutics. It also signed a multiyear supply contract with Motif, whose less-invasive neurostimulation device is initially aimed at treatment-resistant depression.
If MintNeuro’s chips reach commercial scale, they may lower barriers for neurotech developers, potentially speeding research and product development for implants and brain-computer interfaces. Patients with conditions such as treatment-resistant depression could benefit if devices become smaller, more efficient, or easier to build. Clinicians, device makers, and investors may also be affected as a specialized semiconductor supply chain emerges. Yet real-world impact will depend on clinical validation, regulatory review, and whether partners can turn prototypes into accessible therapies.